Pfizer Inc PFE

Morningstar Rating
$28.47 −0.39 (1.35%)
View Full Chart

Company Report

Price vs Fair Value

PFE is trading at a LOCK|NtlZGd? premium.
Price
$28.86
Fair Value
hGZ
Uncertainty
LOCK|$%v>
1-Star Price
LOCK|.q
5-Star Price
LOCK|.SK
Economic Moat
LOCK|<#xz
Capital Allocation
LOCK|T?GFtf?

Bulls Say, Bears Say

Bulls

Pfizer's portfolio contains several blockbusters, including differentiated cardiovascular drug Vyndamax and oncology drug Padcev.

Bears

Aggressive cost-cutting in research and development could hurt Pfizer's long-term prospects, given the importance of continued investment in innovation.

News

Articles & Videos

Trading Information

Previous Close Price
$28.86
Day Range
$28.35–28.67
52-Week Range
$23.62–31.44
Bid/Ask
$28.45 / $28.51
Shares Outstanding
5.70B
Market Cap
$162.27B
Volume/Avg
35M / 34M

Key Statistics

Price/Earnings (Normalized)
13.28
Price/Sales
2.60
Dividend Yield (Trailing)
5.96%
Dividend Yield (Forward)
5.96%
Dividend Payment Schedule
Mar, Jun, Sep, Dec
Total Yield
5.96%

Company Profile

Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13 and cardiology drugs Vyndamax and Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
Sector
Healthcare
Industry
Drug Manufacturers - General
Stock Style Box
Large Value
Total Number of Employees
75,000

Competitors

Valuation

Metric
PFE
MRK
GSK
Price/Earnings (Normalized)
13.28107.3213.73
Price/Book Value
1.857.944.07
Price/Sales
2.605.312.29
Price/Cash Flow
11.1916.1510.15
Price/Earnings
PFE
MRK
GSK

Financial Strength

Metric
PFE
MRK
GSK
Quick Ratio
1.000.780.55
Current Ratio
1.421.350.86
Interest Coverage
2.393.338.21
Quick Ratio
PFE
MRK
GSK

Profitability

Metric
PFE
MRK
GSK
Return on Assets (Normalized)
8.49%2.53%11.16%
Return on Equity (Normalized)
19.73%7.02%40.86%
Return on Invested Capital (Normalized)
12.71%4.79%21.39%
Return on Assets
PFE
MRK
GSK

Drug Manufacturers - General Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Eli Lilly and Co
LLY
LOCK|gxJb&R!>LOCK|^k$1T
Johnson & Johnson
JNJ
LOCK|^tZ#R$pLOCK|Jmc$680B
AbbVie Inc
ABBV
LOCK|Nw!H^ZLOCK|dL!$521B
Roche Holding AG ADR
RHHBY
LOCK|<&r@Skr@LOCK|><$389B
Merck & Co Inc
MRK
LOCK|><LKNcTLOCK|zW$356B
Novartis AG ADR
NVS
LOCK|Jlc^MyvLOCK|R<$306B
AstraZeneca PLC
AZN
LOCK|J&h<FN^YLOCK|!?#$288B
Amgen Inc
AMGN
LOCK|g<#ysKZHLOCK|qx$250B
Gilead Sciences Inc
GILD
LOCK|Q%Y@%dLOCK|jSF$208B
Novo Nordisk AS ADR
NVO
LOCK|>%DJH!>LOCK|GM$185B

Sponsor Center